India’s CDMO opportunity is very huge, but regulatory delays could hurt, warns Laurus Labs CEO
Laurus Labs has expanded its R&D footprint in Genome Valley with over 1,000 scientists and a half-million square feet of research space. The company is also building a new facility for cell and gene therapy as well as antibody-drug conjugates, which is expected to be operational by the end of next year.

What's Your Reaction?






